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Abstract
Background: The acellular fraction of epithelial ovarian cancer (EOC) ascites promotes de novo resistance of tumor
cells and thus supports the idea that tumor cells may survive in the surrounding protective microenvironment
contributing to disease recurrence. Levels of the pro-inflammatory cytokines IL-6 and IL-8 are elevated in EOC
ascites suggesting that they could play a role in tumor progression.
Methods: We measured IL-6 and IL-8 levels in the ascites of 39 patients with newly diagnosed EOC. Commercially
available enzyme-linked immunosorbent assay (ELISA) was used to determine IL-6 and IL-8 ascites levels. Ascites
cytokine levels were correlated with clinicopathological parameters and progression-free survival.
Results: Mean ascites levels for IL-6 and IL-8 were 6419 pg/ml (SEM: 1409 pg/ml) and 1408 pg/ml (SEM: 437 pg/ml)
respectively. The levels of IL-6 and IL-8 in ascites were significantly lower in patients that have received prior
chemotherapy before the surgery (Mann-Whitney U test, P = 0.037 for IL-6 and P = 0.008 for IL-8). Univariate analysis
revealed that high IL-6 ascites levels (P = 0.021), serum CA125 levels (P = 0.04) and stage IV (P = 0.009) were
significantly correlated with shorter progression-free survival. Including these variables in a multivariate analysis
revealed that elevated IL-6 levels (P = 0.033) was an independent predictor of shorter progression-free survival.
Conclusion: Elevated IL-6, but not IL-8, ascites level is an independent predictor of shorter progression-free
survival.
Background
The incidence of ascites in women presenting with epithe-
lial ovarian cancer (EOC) ranges from 45% to 75% depend-
ing on the tumor type but increases in advanced stages [1].
It is a distressing complication carrying substantial morbid-
ity [2]. Unlike most stroma surrounding solid tumors,
ascites constitute a unique form of tumor microenviron-
ment. Recent evidences suggest than ascites play an active
role in tumor development. EOC ascites may affect cell
behaviour such as cell growth, invasion, and de novo drug
resistance of EOC cells [3-5]. We recently reported that
the acellular fraction of EOC ascites inhibits drugs- and
death receptor-induced apoptosis in vitro (de novo resis-
tance) [3,4]. Newly diagnosed women with protective
ascites had significantly shorter progression-free survival
[ 6 ]s u g g e s t i n gt h a ta s c i t e s - m e d i a t e dde novo resistance
impacts on EOC progression. Stromal myofibroblasts and
endothelial cells, adjacent to cancer cells in solid tumors,
are replaced by floating mesothelial cells and by a variety of
immune cells in ascites. The acellular fraction of ascites is a
complex exudative fluid known to contain growth factors
[7-9], lysophosphatidic acid (LPA) [10,11], cytokines
[12,13] and extracellular matrix constituents (ECM) [14].
The contribution of these molecules in ovarian cancer pro-
gression is not well defined.
Although a wide variety of cytokines can be measured in
ovarian cancer ascites, interleukin-6 (IL-6) and interleu-
kin-8 (IL-8) are among the most abundant [12]. The con-
centration of these pro-inflammatory cytokines in ascites
is 40- to 500-fold higher as compared to the levels found
in serum [12]. IL-6 can be secreted in ascites by ovarian
cancer cells, tumor-associated macrophages and peritoneal
mesothelial cells. However, levels of IL-6 secreted by
mesothelial cells are 600-fold higher than those secreted
by ovarian cancer cells [15]. The source of the IL-8 found
in ascites has not been well defined. These pro-inflamma-
tory cytokines are involved in different pathophysiological
processes including carcinogenesis. In ovarian cancer, IL-6
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any medium, provided the original work is properly cited.is thought to be involved in host immune responses to the
disease [16-18]. IL-6 has also been demonstrated to be
involved in autocrine growth of ovarian cancer cells
[19-21]. IL-6 signaling in ovarian cancer cells can regulate
tumor cell proliferation, invasion and angiogenesis [22-24]
IL-8 was recently reported to promote ovarian tumor
growth in vivo [25]. Despite these data, the biological rele-
vance of high levels of IL-6 and IL-8 in ovarian cancer
ascites remains mostly unknown. A number of studies
have reported an association between serum levels of IL-6
and prognosis, and elevated levels correlated with a poor
relapse-free and overall survival [26,27]. However, others
have not found such correlation between elevated serum
levels of IL-6 and survival time [28].
Based on the observation that ovarian cancer ascites
may affect tumor progression and reported elevated
levels of IL-6 and IL-8 in ascites, we hypothesize that
these cytokines might affect the clinical progression of
patients with ovarian cancer. The purpose of the present
study was to investigate the prognostic significance of
IL-6 and IL-8 ascites levels on progression-free survival
in a cohort of 39 ovarian cancer patients.
Methods
Patients
The study population consisted of 39 patients with newly
diagnosed epithelial ovarian cancer admitted at the Centre
Hospitalier Universitaire de Sherbrooke. Informed consent
was obtained from women that undergone surgery by the
gynecologic oncology service between 2000 and 2009 for
this institutional review board approved protocol. Baseline
characteristics and serum CA125 levels were collected for
all patients. All patients had a follow up > 1 year. Disease
progression was defined by either CA125 ≥ 2×n a d i r
value on two occasions, documentation of increase or new
lesions on CT-scan or death [29]. Patient’s conditions
were staged according to the criteria of the International
Federation of Gynecology and Obstetrics (FIGO).
Ascitic fluids
Peritoneal fluids were obtained at the time of initial cytor-
eductive surgery for all patients. Peritoneal fluids were
centrifuged at 1000 rpm for 15 min and supernatants were
stored at -80°C until assayed. All fluids were supplied by
the Banque de tissus et de données of the Réseau de
Recherche sur le Cancer des Fonds de la Recherche en
Santé du Québec affiliated to the Canadian Tumor Reposi-
tory Network (CTRNet).
Determination of IL-6 and IL-8 concentration
Determination of IL-6 and IL-8 concentration was per-
formed using the commercially available Quantikine kits
from R&D Systems (Minneapolis, MN). The detection
thresholds were 0.79 pg/ml for IL-6 and 3.5 pg/ml for
IL-8. The intra-assay variability was for IL-6 and IL-8
analysis was 5-10% and 5-20% respectively. All tests
were run in duplicates according to the manufacturer’s
instructions.
Statistical analysis
Comparison between unpaired groups was made using the
Mann-Whitney test or the Kruskal-Wallis test. The
Kaplan-Meier method was used for the progression-free
survival and Cox regression analysis and log-rank test
were used for the statistical analysis. Progression-free sur-
vival was defined as the interval between the surgery and
the time of disease progression. Univariate and multivari-
ate analyses were performed using Cox regression. The
threshold for statistical significance is a probability of 0.05.
Results
A group of 39 patients with newly diagnosed epithelial
ovarian cancer and for which ascites was available was
evaluated. The mean concentration of IL-6 and IL-8 was
determined by ELISA in the 39 ascites samples. The
patient’s clinicopathological characteristics are summar-
ized in Table 1 according the IL-6 and IL-8 ascites levels.
Mean ascites levels for IL-6 and IL-8 were 6419 pg/ml
(SEM: 1409 pg/ml) and 1408 pg/ml (SEM: 437 pg/ml)
respectively. We found no significant correlation between
IL-6 or IL-8 ascites levels and FIGO stage, histopathol-
ogy, grade, serum CA125 levels or the presence of post-
operative residual tumor (> 2 cm). However, the levels of
IL-6 and IL-8 in ascites were significantly lower in
patients that have received prior chemotherapy before
the surgery (Mann-Whitney U test, P = 0.037 for IL-6
and P = 0.008 for IL-8). It should be noted that the num-
ber of patients with post-operative residual tumor was
limited (n = 4).
Progression-free survival analysis in the overall patient
population showed a shorter progression-free survival for
patients with a median IL-6 ascites levels > 2662 pg/ml
as compared with those presenting with a median IL-6
levels < 2662 pg/ml (log rank test, P =0 . 0 2 1 )( F i g u r e1 ) .
Median progression-free survival was 14 months for
patients with high IL-6 levels versus 24 months for those
with low IL-6. A cutoff value of 2662 pg/ml was selected
according to the median ascites levels in the 39 patients.
Patients with high levels of IL-6 were 2.3 times (95% CI,
1.09 - 4.84) more likely to have disease progression as
compared to those with low (< 2662 pg/ml) IL-6 ascites
levels. High levels of IL-8 (median ≥ 301 pg/ml) were not
significantly associated with increased risk of disease pro-
gression or shorter progression-free survival (Figure 1).
Univariate analysis showed that high IL-6 ascites levels
(P = 0.021), serum CA125 levels (P = 0.04) and stage IV
(P = 0.009) were significantly correlated with shorter
progression-free survival (Table 2). Entering these
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that median IL-6 ascites levels > 2662 pg/ml was an
independent predictor variable of shorter progression-
free survival (P = 0.033). Although it did not quite reach
statistical significance (P = 0.076), entering residual
tumor > 2 cm in the multivariate model still showed
that high IL-6 levels was significantly correlated with
shorter progression-free survival.
Discussion
The successful treatment of EOC remains a major chal-
lenge. Most (> 85%) EOC patients presenting with
advanced disease will relapse. Recurrence defines incur-
able disease in most cases. The main obstacle to effec-
tive treatment is the failure of initial therapy to
eradicate a sufficient number of tumor cells to prevent
disease recurrence. One emerging model for the
Table 1 IL-6 and IL-8 ascites levels in relation to different clinicopathological parameters
No of ascites tested (%) IL-6 mean pg/ml
(SEM)
IL-8 mean pg/ml
(SEM)
Total 39 6419 (1409) 1408 (437)
Stage
I 9 (23) 4526 (3081) 1447 (997)
II 4 (10) 8893 (4719) 2738 (1786)
III 15 (39) 6550 (2521) 1181 (685)
IV 11 (28) 6514 (1869) 1119 (607)
Histopathology
Serous 26 (67) 5209 (1484) 801 (339)
Mucinous 3 (8) 12641 (7227) 3375 (2596)
Mixed 7 (18) 8916 (4084) 2991 (1500)
Endometrioid 1 (2) 7896 (0) 463(0)
Other 2 (5) 1277 (583) 1268 (590)
Grading
a
1 4 (10) 3102 (1625) 228 (82)
2 10 (27) 8482 (3181) 842 (538)
3 20 (51) 5831 (1739) 1755 (661)
Residual tumor
a
≤ 2 cm 34 (87) 6286 (1487) 1555 (495)
> 2 cm 4 (10) 7457 (731) 378 (155)
Prior chemotherapy
a
Yes 4 (10) 444 (111) 430 (123)
No 34 (87) 6984 (1453)
b 1972 (681)
b
Serum CA125
a
< 319 19 (49) 4063 (1841) 1372 (806)
> 319 19 (49) 4406 (1765) 1491 (788)
a Data unavailable for grade (n = 4), residual tumor (n = 1), prior chemotherpay (n = 1), serum CA125 (n = 1)
b IL-6, P = 0.0001; IL-8, P = 0.002
IL-6 < 2662 pg/ml
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Figure 1 Kaplan-Meier analysis of progression-free survival in patients with or without elevated levels of IL-6 and IL-8 in ascites.
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ascites as a tumor microenvironment that promotes de
novo drug resistance. Acellular fractions of EOC ascites
have been shown to have anti-apoptotic activities [3,4]
and ascites with pro-survival activities against cytotoxic
agents were recently shown to significantly correlate
with shorter progression-free survival in ovarian cancer
patients [6]. These findings suggest that EOC ascites
contain factors that affect progression-free survival by
promoting tumor cell survival. EOC ascites contain a
variety of soluble factors, including cytokines, which
may contribute to de novo resistance of tumor cells.
Because of the high levels of IL-6 and IL-8 found in
ascites and the prosurvival activity of ascites, we
hypothesized that IL6 and IL-8 could impact on pro-
gression-free survival. The identification of biomarkers
that predict tumor progression would contribute to stra-
tify patients for the selection of initial therapy.
We measured IL-6 and IL-8 levels in ascites samples
obtained at the time of the initial surgery in a group of
39 patients with previously untreated EOC. Mean ascites
levels of IL-6 and Il-8 found in our cohort were com-
parable to those previously reported by Giuntoli et al.i n
22 ascites samples from women with EOC [12]. Our
results show that elevated IL-6, but not IL-8, levels in
ascites of patients with EOC correlated with shorter
progression-free survival. We found low IL-6 levels to
correlate significantly with prior chemotherapy (P =
0.037). However, these data should be considered with
caution given the small number of patients in the group
that received chemotherapy prior to their surgery. No
significant correlation was found between IL-6 and IL-8
levels in ascites and the other clinicopathological para-
meters such as stage, grade, histologic type and size of
residual tumor left after initial debulking. These data are
consistent with those of Tempfer et al.[ 2 6 ]a n dS c a m -
bia et al.[ 2 7 ]w h i c hs h o w e dt h a te l e v a t e dI L - 6c o n c e n -
t r a t i o ni ns e r u mo fo v a r i a nc a n c e rp a t i e n t sc o r r e l a t e d
with poor overall survival. They are also consistent with
the observation that IL-6 promoter polymorphism,
which may affect IL-6 levels, impacts on survival of
women with ovarian cancer [30]. However, measuring
IL-6 in ascites might actually be more relevant than
measuring it in serum. IL-6 is released by the peritoneal
mesothelial cells and concentrates in ascites [12,15]
where it could affect tumor cell behaviour. IL-6 may be
cleared rapidly from the circulation and consequently
serum levels may not correlate with ascites levels.
Although, our data suggest that IL-6 levels in ascites are
associated with shorter progression-free survival, the pre-
cise underlying molecular mechanisms responsible for
these findings remain to be established. One possibility is
that elevated ascites IL-6 levels promote de novo tumor
cells resistance to chemotherapy contributing to earlier
disease recurrence [31]. This is supported by the observa-
tion that IL-6 inhibited death receptor-induced cell death
in long term cell viability assays (Lane, unpublished data).
IL-6 signaling cascade in ovarian cancer cells has been
associated with the development of Taxol resistance
[32,33]. Alternatively, IL-6 could stimulate the prolifera-
tion of tumor cells leading to a shorter progression-free
survival [18]. IL-6-mediated angiogenesis could also play a
role [23]. Tumor angiogenesis plays an important role in
cancer progression and metastasis. The angiogenesis and
the disruption of vascular barrier both contribute to
ascites formation [34]. Because IL-6 has been shown to be
involved in tumor angiogenesis in ovarian cancer, IL-6
may be important in promoting the formation of ascites as
well as the progression of ovarian cancer. IL-6 signalling
prevents chemotherapy-induced endothelial cells apopto-
sis and the blockage of its signalling cascade was therapeu-
tically beneficial in xenograft mouse model [35]. Thus,
interference with IL-6 pathway may offer opportunities for
ovarian cancer therapy. However, using a monoclonal
antibody that specifically blocks IL-6 signaling, siltuximab,
Guo et al. demonstrated that although the combination of
siltuximab with paclitaxel increased the sensitivity of ovar-
ian tumor cells to paclitaxel in vitro, the combination was
ineffective in vivo in xenogrft mouse model [36]. Although
clinical trials of monoclonal antibodies to IL-6 for the
treatment of other types of cancer have shown encoura-
ging results [37,38], a clear benefit for patients with ovar-
ian cancer remains to be demonstrated. Finally, the high
levels of IL-6 could enhance the immune suppressive
Table 2 Univariate analysis of progression-free survival
with selected factors
Variable Median progression-free
survival (months)
Univariate
analysis (P value)
IL-6 (pg/ml)
< 2662 24
≥ 2662 14 0.021
Stade
I3 6
IV 14 0.009
Serum CA125 (U/ml)
< 319 29
> 319 14 0.040
Residual tumor
≤ 2c m 2 0
> 2 cm 11 0.076
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expression on tumor associated macrophages and promote
apoptosis in these cells [39]. IL-6 may divert the immune
response from Th1 towards a suppressive Th2 response
although controversial data have been reported [11,40,41].
IL-6 may also contribute to reprogram the tumor adjacent
stromal microenvironment which may facilitate dissemina-
tion to the peritoneal cavity. The contribution of this reac-
tive stromal is being recognized as an important element
for tumor progression [42].
Conclusions
We found that high levels of IL-6 in ascites of newly
diagnosed women with ovarian cancer significantly corre-
lated with shorter progression-free survival. In contrast,
ascites levels of IL-8 did not show such association.
These data suggest that IL-6 could be an important com-
ponent that contributes to ascites-mediated de novo drug
resistance.
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